Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

NCT03732664 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT03732664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03732664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2018
Completion date
March 23, 2023
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk resectable nsclc